This article has Open Peer Review reports available.
Androgen secreting steroid cell tumor of the ovary in a young lactating women with acute onset of severe hyperandrogenism: a case report and review of literature
© Haji et al; licensee BioMed Central Ltd. 2007
Received: 07 July 2007
Accepted: 18 December 2007
Published: 18 December 2007
Steroid cell tumors of the ovary account for less than 0.1% of all ovarian tumors  and these tumours may present at any age in association with interesting presentations related to the hormonal activity and virilizing properties of tumor. Hayes and Scully  reported 63 cases in patients ranging from 2 to 80 years of age. The subtype, not otherwise specified, is associated with androgenic changes in approximately one half of patients with this tumour . In a series of 63 cases from Massachusetts General Hospital, 94% of the tumors were found to be unilateral and 28.6% were malignant . As most of these tumors are diagnosed at an early stage and do not recur or metastasize, little is known about their response to therapies such as chemotherapy or radiation .
We present the case of a 22-year old lactating woman who presented with four months of amenorrhea associated with signs of virilization. Clinical and diagnostic evaluation revealed a right adenexal mass and elevated serum levels of testosterone and she was diagnosed as having a stage 1A androgen secreting steroid cell tumor. In view of the early stage of the disease, she underwent right salpingo-oopherectomy. Histopathological examination and immunohistochemistry confirmed the diagnosis. Two months after surgery she regained normal menses and showed regression of the androgenic changes.
Surgery remains the mainstay of the treatment of gonadotrophin receptor positive steroid cell tumors although medical therapy using Gonadotrophin Releasing Hormone [GnRH analogues has been tried recently in recurrent or inoperable cases. There is no described effective chemotherapy or radiotherapy for this condition.
Steroid cell tumors of the ovary account for less than 0.1% of all ovarian tumors  and these tumors may present at any age in association with interesting presentations related to the hormonal activity and virilizing properties of tumor. Hayes and Scully  reported 63 cases in patients ranging from 2 to 80 years of age. The subtype, not otherwise specified, is associated with androgenic changes in approximately one half of patients with this tumor . In a series of 63 cases from Massachusetts General Hospital, 94% of the tumors were found to be unilateral and 28.6% were malignant . As most of these tumors are diagnosed at an early stage and do not recur or metastasize, little is known about their response to therapies such as chemotherapy or radiation .
Values of Hormone/tumor marker levels
< 4 Units/ml
< 5 mIU/ml
0.1–10 ngm/ml (In an adult female)
The patient underwent an exploratory laparotomy. Intra-operatively the right ovary showed a 5 × 5 cm firm, tan-brown, well-encapsulated mass without any adhesions to surrounding structures and with engorged ovarian vessels. In view of the diagnosis of stage 1A disease, unilateral right salpingo-oopherectomy alone was performed since the frequency of lesions occurring bilaterally in this stage has been reported to be only 6%.
Immunohistochemistry staining was positive for gonadotrophin receptors and vimentin, and negative for alpha-fetoprotein and epithelial membrane antigen, providing evidence in favour of a steroid cell tumor.
At post operative follow-up, two months of surgery, the patient had regained normal menses. Her serum testosterone level had gone down to 0.262-ngm/ml, and there was regression of the abnormal hair pattern. The patient is being followed up regularly with measurement of hormone levels as marker of recurrence.
Ovarian steroid cell tumors account for less than 0.1% of all ovarian tumors. They are grouped under sex-chord stromal tumors and are usually benign, unilateral and characterized by a steroid cell proliferation  &.
They are further divided into three subtypes: stromal leuteoma, Leydig cell tumor, and steroid cell tumor ,  &, the latter being the most common of the three subtypes accounting for approximately 60% of cases.
Steroid cell tumors are associated with androgenic changes with variable frequency, ranging from 12% to over 50 %  &, and they are usually of many years duration &. This case is unique because of its acute presentation, with sudden onset of amenorrhea and signs of virilization, over a four month period, following resumption of menses after a normal delivery.
Historically these tumors have been variously referred to as lipoid cell tumors, lipid cell tumors, adrenal-like tumors, masculinovoblastomas, leutomas, hypernephroid tumors, and adrenal rest tumors, indicating the infidelity of their supposed lineage , , . However, it is postulated that these are of adrenal cortical rest origin, residing near the ovary, on the basis of the presence of mRNA for steroidogenic p450c11 and p450c21, which are expressed only in tissues of adrenal origin . However this theory is still disputed .
The majority of steroid cell tumors have a benign or low-grade behavior. Interestingly, pathologically-benign tumors can behave in a clinically malignant fashion . About 20% patients develop metastatic lesions usually within the peritoneal cavity, and rarely at distant sites  &. In a series of 63 cases from the Massachusetts General Hospital, 94% of the tumors were found to be unilateral, and 28.6% cases had features suggestive of malignant nature .
Hayes and Scully  have identified five pathologic features that are highly associated with malignancy: More than two mitoses per high-power field; necrosis; size of 7 cm or larger; hemorrhage; and Grade 2 or 3 nuclear atypia. The final pathologic diagnosis is based on the characteristic histological appearance, including polygonal to round cells with distinct cell borders and an abundant cytoplasm and the absence of Reinke's crystals, and a characteristic pattern of immunohistochemistry staining for inhibin and vimentin [75%], anti human cytokeratin [46%], and AE1/AE3 [37%] .
The primary treatment is surgical extirpation of the primary lesion, and there are no reports of effective radiation or chemotherapy . In a young patient with stage IA disease, a unilateral salpingo-oophorectomy is adequate since the frequency of bilateral occurrence is only 6% ( ,  &).
The main reason for poor understanding of the therapeutic value of chemotherapy and radiotherapy in the treatment of these tumors is due to the rarity of this tumor. In recent years attempts have been made to describe the use of Gonadotrophin Releasing Hormone [GnRH] analogues to induce a suppression of secretions and an apoptosis leading to a non-surgical cure ,  &. Pascale, Pugeat and Roberts suggested that androgen secretion by ovarian virilizing tumor is gonadotrophin dependent . They concluded that various ovarian androgen secreting tumors are not autonomous but apparently depend on continuous gonadotrophin stimulation.
Imai A, Lida K, Tamaya T suggested the various relationships between GnRH receptor and tumor growth. Increased Fas ligand level within GnRH receptor-bearing tumors might promote apoptotic cell death through an attack on intra-tumoral Fas positive cells that could, at least in part, account for the anti-proliferative action of the hormone . The coupling of GnRH receptor to the Gi protein subfamily may be a signaling pathway by which GnRH acts in peripheral tumor .
So far these approaches have been tried primarily in non-operable cases or recurrent disease. Therefore, at best, these treatments can be considered experimental in the present times. Further insight into the nature, biology and behavior of these tumors may change the gold standard of treatment from surgical extirpation to medical management over time.
Ovarian steroid cell tumors, grouped under sex-chord stromal tumors, account for less than 0.1% of all ovarian tumors. They are usually benign, unilateral and are characterized by a steroid cell proliferation  &. These tumors present with long history of often many years of androgenic changes with variable frequency, ,  &. This case is unique because of its acute presentation over a four month period. The primary treatment is surgical extirpation of the primary lesion, and there are no reports of effective treatment with radiation or chemotherapy . In a young patient with stage IA disease, a unilateral salpingo-ophorectomy is adequate since the frequency of bilateralism is only 6% ,  &.
The patient was informed about the intent to publish this report and consented to the same in writing.
We acknowledge Dr. Hiran from department of Pathology, Amrita Institute of Medical Sciences and Research Centre for his contribution in terms of providing slides. No funding was provided by any agency.
- Young RH, Shully RE: Steroid cell tumors of the ovary. Obstetric & Gynecological Pathology. Edited by: Fox H, Wells M. 2003, Spain, Churchill Livingstone, 845-856.Google Scholar
- Hayes MC, Scully RE: Ovarian steroid cell tumors [not otherwise specified]: a clinicopathological analysis of 63 cases. Am J Surg Pathol. 1987, 11: 835-845. 10.1097/00000478-198711000-00002.View ArticlePubMedGoogle Scholar
- Scully RE, Young RH, Clement PB: Steroid cell tumors. Tumors of the Ovary, Mal-developed Gonads, Fallopian Tube, and Broad Ligament. 1996, Washington, DC: Armed Forces Institute of Pathology, 227-238.Google Scholar
- Young RH, Scully RE: Sex cord-stromal, steroid cell, and other ovarian tumors with endocrine, paraendocrine, and paraneoplastic manifestations. Blaustein's Pathology of the Female Genital Tract. Edited by: Kurman RJ. 1994, New York, Springer-Verlag, 783-847.View ArticleGoogle Scholar
- Powell JL, Dulaney DP, Shiro BC: Androgen-secreting steroid cell tumor of the ovary. South Med J. 2000, 93 (12): 1201-1204.View ArticlePubMedGoogle Scholar
- Paraskevas M, Schully Re: Hilus cell tumor of the ovary. Int J Gynecol Pathol. 1989, 8: 299-309.View ArticlePubMedGoogle Scholar
- Staels B, Hun DW, Miller WL: Regulation of steroidogenesis in NCI-H295 cells: a cellular model for human fetal adrenal. Mol Endocrinol. 1993, 7: 423-433. 10.1210/me.7.3.423.PubMedGoogle Scholar
- Clement PB, Young RH: Atlas of Gynecologic Surgical Pathology. 2000, Philadelphia, Pa: WB Saunders CoGoogle Scholar
- Barakat RR, Rubin SC, Wong G: Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases. Obstet Gynecol. 1992, 80: 660-4.PubMedGoogle Scholar
- Karlan BY, Markman MA, Eifel PJ: Sex-cord Stromal Tumors. Cancer: Principles and Practice of Oncology. Edited by: DeVita VT Jr, Hellman S, Rosenberg SA. 2005, Philadelphia, Lippincott Williams & Wilkinson, 1392-1393.Google Scholar
- Pascale MM, Pugeat M, Roberts M: Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumors. Clin Endocrinol (Oxf). 1994, 41 (5): 571-576.View ArticleGoogle Scholar
- Imai A, Lida K, Tamaya T: Direct action of gonadotrophin-releasing hormone [LHRH] analogue on ovary: an alternative acting mechanism of buserelin. Arch Gynecol Obstet. 1991, 248: 117-12l. 10.1007/BF02390088.View ArticlePubMedGoogle Scholar
- Stephens JW, Katz JR, McDermott N, MacLean AB, Bouloux P-MG: An unusual steroid producing ovarian tumor. Human Reproduction. 2002, 17 (6): 1468-1471. 10.1093/humrep/17.6.1468.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.